KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Finished Goods (2016 - 2018)

Teva Pharmaceutical Industries (TEVA) has disclosed Finished Goods for 8 consecutive years, with $2.7 billion as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Finished Goods changed N/A year-over-year to $2.7 billion, compared with a TTM value of $2.7 billion through Dec 2018, changed N/A, and an annual FY2018 reading of $2.7 billion, changed N/A over the prior year.
  • Finished Goods was $2.7 billion for Q4 2018 at Teva Pharmaceutical Industries, down from $2.7 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $2.8 billion in Q4 2016 and bottomed at $2.1 billion in Q4 2015.
  • Average Finished Goods over 4 years is $2.6 billion, with a median of $2.7 billion recorded in 2018.
  • The sharpest move saw Finished Goods decreased 11.65% in 2014, then soared 38.15% in 2016.
  • Year by year, Finished Goods stood at $2.3 billion in 2014, then fell by 9.61% to $2.1 billion in 2015, then surged by 38.15% to $2.8 billion in 2016, then dropped by 5.9% to $2.7 billion in 2018.
  • Business Quant data shows Finished Goods for TEVA at $2.7 billion in Q4 2018, $2.7 billion in Q3 2018, and $2.7 billion in Q2 2018.